These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3275719)

  • 1. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum.
    Etlinger HM; Felix AM; Gillessen D; Heimer EP; Just M; Pink JR; Sinigaglia F; Stürchler D; Takacs B; Trzeciak A
    J Immunol; 1988 Jan; 140(2):626-33. PubMed ID: 3275719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment in mice of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, P. falciparum.
    Etlinger HM; Heimer EP; Trzeciak A; Felix AM; Gillessen D
    Immunology; 1988 Jul; 64(3):551-8. PubMed ID: 3044983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha and synthetic peptide malaria sporozoite vaccine in non-immune adults: antibody response after 40 weeks.
    Stürchler D; Zimmer G; Berger R; Etlinger H; Fernex M; Matile H; Just M
    Bull World Health Organ; 1990; 68 Suppl(Suppl):38-41. PubMed ID: 2094589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of 5.1-[NANP]19, a recombinant Plasmodium falciparum vaccine candidate, in adults.
    Stürchler D; Just M; Berger R; Reber-Liske R; Matile H; Etlinger H; Takacs B; Rudin C; Fernex M
    Trop Geogr Med; 1992 Jan; 44(1-2):9-14. PubMed ID: 1496731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses to a synthetic peptide-based malaria vaccine candidate: influence of sequence variants of the peptide.
    Etlinger HM; Renia L; Matile H; Manneberg M; Mazier D; Trzeciak A; Gillessen D
    Eur J Immunol; 1991 Jun; 21(6):1505-11. PubMed ID: 2044658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso)].
    Guiguemdé TR; Sturchler D; Ouédraogo JB; Drabo M; Etlinger H; Douchet C; Gbary AR; Haller L; Kambou S; Fernex M
    Bull Soc Pathol Exot; 1990; 83(2):217-27. PubMed ID: 2119897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic peptide immunogens eliciting antibodies to Plasmodium falciparum sporozoite and merozoite surface antigens in H-2b and H-2k mice.
    Rzepczyk CM; Csurhes PA; Lord R; Matile H
    J Immunol; 1990 Oct; 145(8):2691-6. PubMed ID: 2212657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.
    Herrington DA; Clyde DF; Losonsky G; Cortesia M; Murphy JR; Davis J; Baqar S; Felix AM; Heimer EP; Gillessen D
    Nature; 1987 Jul 16-22; 328(6127):257-9. PubMed ID: 2439920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: possible implications for malaria vaccines.
    Del Giudice G; Cooper JA; Merino J; Verdini AS; Pessi A; Togna AR; Engers HD; Corradin G; Lambert PH
    J Immunol; 1986 Nov; 137(9):2952-5. PubMed ID: 3531341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of antibodies to Plasmodium falciparum sporozoites by employing synthetic peptides.
    Del Giudice G; Biro S; Degrémont AA; Engers HD; Lambert PH; Pessi A; Tougne C; Verdini AS; Weiss N; Tanner M
    Parassitologia; 1986; 28(2-3):107-11. PubMed ID: 3332303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites.
    Herrington DA; Clyde DF; Davis JR; Baqar S; Murphy JR; Cortese JF; Bank RS; Nardin E; DiJohn D; Nussenzweig RS
    Bull World Health Organ; 1990; 68 Suppl(Suppl):33-7. PubMed ID: 2094588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody responses to Plasmodium falciparum and P. vivax sporozoites in areas with stable and unstable malaria.
    Del Giudice G; Lambert PH; Mendis K; Pessi A; Tanner M
    Bull World Health Organ; 1990; 68 Suppl(Suppl):191-6. PubMed ID: 2094587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of ELISAs employing repetitive peptides to detect antibodies to Plasmodium falciparum sporozoites.
    Del Giudice G; Douglas A; Verhave JP; Wirtz RA; Zavala F
    Bull World Health Organ; 1989; 67(5):515-23. PubMed ID: 2692868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults.
    Stürchler D; Berger R; Etlinger H; Fernex M; Matile H; Pink R; Schlumbom V; Just M
    Vaccine; 1989 Oct; 7(5):457-61. PubMed ID: 2479187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.
    Epstein JE; Charoenvit Y; Kester KE; Wang R; Newcomer R; Fitzpatrick S; Richie TL; Tornieporth N; Heppner DG; Ockenhouse C; Majam V; Holland C; Abot E; Ganeshan H; Berzins M; Jones T; Freydberg CN; Ng J; Norman J; Carucci DJ; Cohen J; Hoffman SL
    Vaccine; 2004 Apr; 22(13-14):1592-603. PubMed ID: 15068840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential non-responsiveness in humans of candidate Plasmodium falciparum vaccine antigens.
    Quakyi IA; Otoo LN; Pombo D; Sugars LY; Menon A; De Groot AS; Johnson A; Alling D; Miller LH; Good MF
    Am J Trop Med Hyg; 1989 Aug; 41(2):125-34. PubMed ID: 2672834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and humoral immune responses to a recombinant P. falciparum CS protein in sporozoite-immunized rodents and human volunteers.
    Nardin EH; Nussenzweig RS; Altszuler R; Herrington D; Levine M; Murphy J; Davis J; Bathurst I; Barr P; Romero P
    Bull World Health Organ; 1990; 68 Suppl(Suppl):85-7. PubMed ID: 2094595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa.
    Sirima SB; Nébié I; Ouédraogo A; Tiono AB; Konaté AT; Gansané A; Dermé AI; Diarra A; Ouédraogo A; Soulama I; Cuzzin-Ouattara N; Cousens S; Leroy O
    Vaccine; 2007 Mar; 25(14):2723-32. PubMed ID: 17280744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a synthetic malaria vaccine: cyclization of a peptide eliminates the production of parasite-unreactive antibody.
    Etlinger HM; Trzeciak A
    Philos Trans R Soc Lond B Biol Sci; 1993 Apr; 340(1291):69-72. PubMed ID: 8099745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.